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Open access under CCRheumatoid arthritis (RA) is a systemic inﬂammatory disease with
a predilection for symmetrically distributed diarthroidal joints. It is
clinically heterogeneous, with particular disease phenotypes
deﬁned according to a complex interplay of genes and the envi-
ronment. In this chapter we ﬁrst summarize current knowledge of
RA genetic susceptibility, a ﬁeld which has been transformed in
recent years by powerful modern genotyping technologies. The
importance of a recently described subclassiﬁcation for the disease
based upon the presence or absence of circulating autoantibodies
to citrullinated peptides has further informed genetic studies, and
we consider the implications for our understanding of RA patho-
genesis. We then review the cellular and molecular processes that
initiate and perpetuate joint destruction.
 2008 Elsevier Ltd. Open access under CC BY-NC-ND license.What genetic factors predispose to rheumatoid arthritis (RA)?
It has long been documented that RA clusters in families: the likelihood that a ﬁrst-degree relative
of a patient will share the diagnosis is 2–10 times the population prevalence of the disease [1]. The
genetic basis of such clustering is conﬁrmed by observations that RA concordance amongst mono-
zygotic twins is approximately 15%, which is up to 5 times greater than in dizygotic twins. Twin studies
permit an estimation of heritability (the extent to which liability to a condition in a population can be.
tt).
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RA has been calculated as 60% [2].
HLA association
The longest-established, and strongest, genetic association of RA is with a particular set of alleles at
the highly polymorphic human leukocyte antigen (HLA)-DRB1 locus on the short arm of chromosome 6
(6p21.3). This gene encodesmajor histocompatability complex (MHC) class-II b-chainmolecules whose
function is in the presentation of antigen to CD4þ T ‘helper’ cells. Alleles associated with RA encode
a conserved amino acid sequence within the binding groove of the ﬁnal MHC class-II heterodimer [3].
These ‘shared epitope’ (SE) alleles display a dose effect with respect to susceptibility, with homozygotic
individuals carrying increased risk over heterozygotes, and particular compound heterozygote
combinations representing a disproportionate risk that achieves odds ratios of >30 [4]. A similar
pattern emerges in respect of disease severity [5]. Genome-wide sibling-pair linkage analyses have
conﬁrmed linkage at the HLA locus amongst American [6] and European [7], but not Japanese [8],
populations, illustrating the importance of ethnic considerations when interpreting genetic studies.
Recently, a distinct class-II MHC b-chain amino-acid sequence has been shown to be protective against
both RA susceptibility and severity in a northern European population, independently of coexisting risk
alleles [9]. The DRB1 allele that encodes this sequence may even confer protection to the offspring of
a womanwho carries it without itself being inherited: a phenomenon termed non-inherited maternal
allele (NIMA) protection [10]. DRB1-gene promoter polymorphisms add an additional layer of
complexity to the picture. For example, differential regulation of respective DRB1 allele expression,
with the potential to inﬂuence MHC phenotype and hence RA susceptibility, may be determined by
polymorphism within the trans-acting HLA class-II promoter gene MHC2TA [11].
Altogether, the HLA region encompasses 3000 kilobases of genomic DNA and, aside fromMHC class-
I and class-II genes, it contains a wide range of other immunologically relevant genes. Many studies
have investigated possible additional associations of such genes with RA susceptibility, but they are
complicated by the inevitable linkage disequilibrium of candidate loci in the regionwith the HLA-DRB1
gene itself (reviewed by Newton et al) [12]. By controlling for SE risk amongst pedigrees and controls,
transmission disequilibrium testing of loci within HLA haplotypes has recently provided strong
evidence that such associations indeed exist [13], but further work is needed to delineate the ﬁndings.
Non-HLA genetic association
The contribution that HLA-DRB1 status makes to the overall heritability of RA has been estimated at
about a third [14], and the search for non-HLA disease associations has therefore been intense.
Investigation of the candidate gene PTPN22, located on chromosome 1 (p13), provided the ﬁrst
deﬁnitive evidence of such an association [15], since extensively validated [16]. A missense C/ T
substitution at base position 1856 of this gene leads to the presence of tryptophan (W) in place of
arginine (R) at residue 620 of the protein product, which is the lymphoid-speciﬁc protein tyrosine
phosphatase, LYP. ‘R620W’ substitution appears to represent a ‘gain-in-function’ mutation which,
through enhanced regulation of T-cell receptor (TCR) signalling during thymic selection, permits
autoantigen-speciﬁc T cells to escape clonal deletion, thereby predisposing to autoimmunity [17]. Once
more, the association does not extend to all ethnic groups, and the R620W variant is not seen in Asian
populations [18].
Innovation in high-throughput biotechnology, coupled with the accumulation of large repositories
of clinical material, has culminated in the completion of the ﬁrst genome-wide association studies
(GWAS). Hundreds of thousands of single-nucleotide polymorphisms (SNPs) may now be genotyped
simultaneously amongst large sample sets in a cost-effective manner. In the pioneering example of the
Wellcome Trust Case Control Consortium (WTCCC) GWAS, DNA samples of 2000 RA patients (and
similar numbers of patients diagnosed with other common complex diseases) were genotyped for over
500,000 SNPs alongside 3000 pooled controls, all drawn from UK populations [19]. This study
conﬁrmed the association of both HLA-DRB1 and PTPN22 with RA, and strong evidence of association
was suggested at nine additional loci. Only one of these, on chromosome 6 (6q23), has since been
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region concerned lies in proximity to the TNF-a-induced protein 3 (TNFAI3) gene, whose product
functions as a negative regulator of nuclear factor kB (NFkB), a transcription factor involved in the
propagation of many inﬂammatory pathways. In separate case–control cohorts from US and Swedish
populations, the GWAS approach has identiﬁed a further region of association on the long arm of
chromosome 9 (9q33–34), which contains genes encoding both tumour-necrosis-factor-associated
factor-1 (TRAF-1) and C5 complement [22]. Both products may play a role in the propagation of
inﬂammatory responses, and although the ﬁndings have been independently replicated in European
cohorts [23,24], functional studies will be needed to further reﬁne the TRAF-1/C5 association.
Smaller-scale SNP association analyses have generated conﬂicting results for several additional gene
loci. The inconsistent ﬁnding of RA association with the þ49G allele at the cytotoxic-T-lymphocyte-
associated antigen 4 (CTLA-4) gene [25], along with the ﬁnding of only nominal association at this locus
in the WTCCC study, is probably inﬂuenced by differences in the demographics of the various pop-
ulations studied. A meta-analysis of this association demonstrated a striking bias towards positive
studies in Asian and Far-Eastern, rather than white Caucasian, populations [25], and taken together it
seems likely that the polymorphism inﬂuences disease susceptibility predominantly in non-Euro-
peans. CTLA-4 is a candidate gene for RA since its product, expressed exclusively by T-cells, has an
important role in down-regulating CD28-mediated T-cell co-stimulation, thereby attenuating T-cell
activation [26]. Another previously identiﬁed genetic association with RA that appears to be relatively
restricted to Asian populations involves the PADI4 gene, situated on the short arm of chromosome 1
(1p36.13) [27]. It encodes peptidyl arginine deiminase isotype 4 (PAD4), which is predominantly
expressed by bone marrow and white blood cells, including those found within the rheumatoid
synovium, where it catalyses the post-translational modiﬁcation of arginine to citrulline [28]. Finally,
robust evidence for allelic association of RA with signal transducer and activator of transcription-4
(STAT-4) gene polymorphism has recently emerged [24,29]. STAT-4, encoded on chromosome 2, is
known to be up-regulated in RA synovium and, following the ligation of surface-expressed IL-12
receptor on CD4þ T cells, plays a role in skewing the effector phenotype of this cell type during
maturation [24,30].Further considerations
A range of other potential genetic associations with RA remains the subject of investigation, and
stands to provide additional important insight into the pathogenesis of the disease. However, based on
recent discoveries, the effect of any newly conﬁrmed genetic association is likely to be small in terms of
attributable risk, attaining an odds ratio of little more than 1.Whilst HLA and PTPN22 together probably
make up about half of the stated genetic contribution to RA susceptibility, it is hard to see how the
additive effects of additional minor genetic determinants might together make up the remaining 50%
of the disease’s heritability. As our understanding of the environmental risk factors for developing RA
continues to grow [31], it is increasingly apparent that gene–environment interactions explain this
phenomenon to a signiﬁcant extent. Similarly, distinct genetic risk factors may provide multiplicative,
rather than merely additive, combined risk because of their compound molecular consequences.
Autoantibodies and the genetic epidemiology of RA
The importance of ACPA (anti-cyclic citrullinated peptide antibody; anti-CCP) status in stratifying
risk for RA has been a highly signiﬁcant discovery. The peptidyl arginine deiminase-dependent
conversion of positively-charged arginine to neutral citrulline occurs ubiquitously in health, taking
place preferentially at supranormal intracellular calcium concentrations [28]. By contrast, the presence
of circulating ACPAs, detectable using now widely available assays, is >95% speciﬁc for RA, with
a sensitivity of around 65% [32]. Moreover, the demonstration that ACPA predates the clinical onset of
arthritis by several years in some patients [33], that it predicts a more severe, erosive natural history
[34], and that citrullinated peptides are present in the rheumatoid synovium [35], all imply a possible
pathogenetic role for the autoantibody.
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factors for the disease – HLA SE [36], PTPN22 [37] and smoking [38] – the predominant effect is seen
only in ACPA-positive patients (Fig. 1). At least in the case of HLA SE, the primary risk factor appears to
be ACPA status itself, in turn inﬂuenced by genotype, rather than the presence of the SE per se [39]. It
has since been demonstrated that tobacco exposure confers a multiplicative risk of RA to SE-positive
individuals, apparently by an ACPA-induced mechanism [40]. A large-scale collaborative epidemio-
logical study duplicated these ﬁndings in Swedish, Dutch and US populations, showing that smoking–
SE interaction increased risk, and that the combined risk conferred by coincidence of relevant HLA SE
and PTPN22 alleles was also multiplicative rather than additive [41]. It should be noted, however, that
the smoking–SE interaction was not reproduced in an independent large US cohort [42], and scope for
identifying additional environmental interactors therefore remains. No such effects were seen amongst
the ACPA-negative RA patients studied. Associations between RA and CTLA-4 [37], as well as the newly-
deﬁned 6q23 and 9q33–34 polymorphisms [20,23], have again been shown to be strongest amongst
ACPA-positive individuals.
ACPA-positive disease: the ‘real’ RA?
It is tempting to draw the conclusion that ACPA status delineates two distinct subsets of a clinically
deﬁned phenotype which happens to satisfy the ACR criteria for RA [43], with all of the latter’s well-
documented shortcomings. One might infer that the histological characteristics of the two conditions
should differ, and this has recently been eloquently demonstrated: ACPA-positive synovium appears to
be characterized by denser lymphocyte inﬁltrations and a higher rate of joint destruction, whereas
more extensive ﬁbrotic changes are apparent in ACPA-negative tissue [44]. Recently a small random-
ized placebo-controlled trial of methotrexate in undifferentiated arthritis demonstrated a potential for
the drug to delay or prevent progression to RA amongst the ACPA-positive but not ACPA-negative
subgroups [45], lending further credence to the concept that these might represent distinct entities
within an overlapping clinical phenotype.
What might we conclude about the induction of autoimmunity in ACPA-positive RA? One salient
observation is that deimination of arginine to citrulline greatly increases the afﬁnity of putative peptide
autoantigens for the positively charged binding groove common to the class-II MHC b-chain products
which incorporate the SE [46]. As recently highlighted by Klareskog and colleagues [47], cigarette
smoke is known to activate lung tissue macrophages and induce apoptosis, providing the increased
calcium concentration necessary for such PAD4-mediated neoantigen formation to take place [48]. It is
known that citrullinated peptides are capable of inducing T-cell responses in mice [49], and additional
failures of central tolerance in humans, facilitated through either PTPN22 or CTLA-4 polymorphism,Anti-CCP-positive RA Anti-CCP-negative RA 
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Fig. 1. Histograms of odds ratios for developing anti-CCP-positive (A) and anti-CCP-negative (B) rheumatoid arthritis (RA) for
different combinations of absence or presence of R620 W PTPN22, single or double HLA-DRB1 shared epitope (SE) alleles, and
smoking (see text). CCP, cyclic citrullinated peptide. Reproduced from Kallberg et al Am J Hum Genet 2007;80:867–75) with
permission.
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ACPA. Against such a background, a subsequent citrullination event within the joint might be sufﬁcient
to trigger an autoimmune arthropathy [47].
This model has attractive elements, but fails to account for a number of additional observations. RA
is predominantly a disease of the joint, yet citrullination is a ubiquitous process that is not tissue-
speciﬁc: what leads to localization of the disease to the synovium? Additionally, neither peptidyl
arginine deiminase I (PADI) enzyme expression [50] nor any of the wide range of potentially auto-
antigenic citrullinated epitopes identiﬁed within RA synovia appears to be speciﬁc for the disease.
Neither have disease-speciﬁc citrulline-reactive Tcells yet been convincingly demonstrated in humans.
Crucially, therefore, whether citrullination in RA in fact represents the initiating step in disease
induction, an upstream indicator of immune dysregulation, or indeed a downstream ‘bystander’
phenomenon, has yet to be ascertained, and continues to be the subject of intense investigation.The elephant in the room: ACPA-negative RA
It seems that, for all that we have gained through a growing understanding of ACPA-positive RA, we
now need to ‘unlearn’ all that we thought we knew about its ACPA-negative counterpart. And it is the
latter condition which remains the hardest to deﬁne and the most likely to be subject to delayed
diagnosis. It might be argued that investigation of this subset should not be a priority, since patients
characteristically experience a less ‘aggressive’ disease in terms of the development of radiographic
progression [34]. However, it should be borne inmind that ACPA-negative RAmay be less responsive to
conventional treatments [45] and, especially where intervention is delayed, ultimately susceptible to
poorer outcomes than ACPA-positive disease. Although genetic associations with this subset of RA
patients have begun to emerge [51], they remain unconﬁrmed and warrant further investigation.
How is synovitis initiated and what leads to chronicity?
The striking heritability of RA, together with the presence of autoantibodies that precede clinical
onset in a subset of patients, supports a pathogenetic model in which autoimmune propensity is long-
established by the time joint inﬂammation is ‘triggered’ (Fig. 2). This concept is further supported by1: “Pre-articular”
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Fig. 2. Various pathogenetic pathways account for the heterogeneity of the early rheumatoid arthritis (RA) phenotype. During both
the pre-articular phase (1) and the triggering of synovitis itself (2), genetic and environmental determinants together induce
a combination of pathogenetic pathways whose common outcome is a syndrome of synovitis ultimately recognizable as RA (3). The
relative contributions of the various pathways in turn deﬁne an individual’s disease phenotype (4). It is hoped that the search for
biomarkers will yield a means of stratifying early RA into prognostically and therapeutically relevant subsets. TLR, ‘Toll-like’
receptor; DMARD, disease-modifying anti-rheumatic drug; IP, inﬂammatory polyarthritis.
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70 gene leads to autoimmune propensity via impaired thymic T-cell selection, but arthritis cannot be
induced in the absence of circulating pro-inﬂammatory cytokines [53]. Amongst rhesus monkeys in
whom arthritis was artiﬁcially induced, microscopic joint inﬂammationwas demonstrable prior to the
clinical onset of disease, and evidence for an analogous ‘preclinical’ phase in humans comes from the
observation that histological synovitis is manifest in the clinically uninvolved joints of RA patients [54].
Interestingly, comparative histology indicates that the synovitis of early RA shares many of the path-
ological features of established disease [55]. Whilst no single cell type or molecular pathway exclu-
sively encapsulates the RA disease process, the relative importance of each probably varies between
individuals in what is a heterogeneous disease (Fig. 2). Areas of particular current interest with regard
to the initiation and persistence of synovitis are discussed here.
An ‘arthritogenic autoantigen’?
Enriched populations of mature antigen-presenting dendritic cells (DCs) are seen in established RA
lesions [56], and animal work supports a role for them in the induction of autoimmune arthritis [57].
The validity of a model in which DC antigen presentation is similarly central to the initiation of human
disease has not been conﬁrmed however, largely because the identity of a dominant arthritogenic
autoantigen has remained elusive. One candidate is human cartilage glycoprotein 39 (HC gp-39) which,
only when processed by antigen-presenting cells expressing the SE, has been shown to yield a unique
set of immunodominant peptides capable of inducing proliferative human T-cell responses ex vivo [58].
Interestingly, T-cell responses against HC gp-39 have since been associated with production of
immunoregulatory interleukin 10 (IL-10) in DRB1*04-positive healthy controls but pro-inﬂammatory
cytokines in DRB1*04-positive RA patients [59]. Other similarly implicated autoantigens include
human type-II collagen and aggrecan. Exposure to Epstein–Barr virus (EBV) and greater EBV viral loads
are associated with RA such that infection by this pathogen has been mooted as a potential arthrito-
genic trigger; whilst intriguing mechanisms have been proposed, they remain unconﬁrmed, however
[60]. DC might alternatively contribute to the circumvention of central tolerance by priming the
immune system to respond to self antigen that has been post-translationally modiﬁed, as might occur
following citrullination.
Fibroblast-like synoviocytes in disease induction
Although not as efﬁcient at processing and presenting antigen as DCs, other cells of the innate
immune system may be better placed to initiate an inﬂammatory process within the joint. Like DCs,
resident ﬁbroblast-like synoviocytes (FLSs) express members of the ‘Toll-like’ receptor (TLR) family
[61] which function in the front line of host defence. As well as recognizing speciﬁc structures of
invading pathogens called pathogen-associated molecular patterns (PAMPs) [62], TLRs have a range of
endogenous ligands, including hyaluronan fragments [63], and high-mobility-group box 1 protein
(HMGB-1) [64], which may appear transiently in the healthy synovium. TLR-2 or -4 engagement in
human RA synovial tissue cultures has recently been shown to induce pro-inﬂammatory mediators,
and the speciﬁc signalling pathways involved are being elucidated [65]. FLSs are also capable of
secreting chemokines, in turn abundant in established RA lesions and largely responsible for the
recruitment and retention of leukocytes at these sites [66]. Examples are CCL2, whose receptor is found
on T cells, monocytes, DCs and basophils, and granulocyte chemotactic protein (GCP-2), both of which
have been shown to be up-regulated in vitro upon TLR-2 ligation by FLS [67]. This cell type appears to
play an additional role in the spatial organization of lymphocytes, once recruited, through the secretion
of stromal-cell-derived factor-1 (SDF-1; CXCL12) [68]. Both FLSs and synovial macrophages can
produce CXCL8 (IL-8), which recruits T cells, basophils and neutrophils, and macrophages may also be
involved in B-cell recruitment via the secretion of CXCL13 (B-cell-attractant-1; BCA-1). Finally, FLSs
have been shown capable of autoantigen presentation to T cells [69]. It is apparent that FLSs represent
an important and previously overlooked player in synovitis initiation, propagation or both, and
synovial stromal cells are as a whole instrumental in creating a microenvironment that favours
inﬂammatory-cell retention and the perpetuation of immune pathology in RA [70]. Indeed, as we learn
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pathways will provide novel therapeutic targets for the treatment of the condition [71].
Vascular factors
The role of the synovial vasculature in the pathogenesis of RA has also gained prominence in recent
years. One tantalizing hypothesis, which arises from elegant mouse work, is that changes in local
vascular permeability might provide a route via which a systemic autoimmune propensity becomes
focused on the synovium [72]. In any event angiogenesis within the hypertrophic synovial sublining is
an important early event in RA, driven by the increased metabolic demands and hypoxia of the
expanding inﬂammatory tissue [73]. New vessels in the RA pannus are of a characteristic branching
morphology [74]. This is thought to result from the unfavourable co-expression by intimal FLSs and
vascular endothelial cells (ECs) of the angiogenic factor VEGF (vascular endothelial growth factor), and
the angiopoietin-1/2–TIE2 complex [73]. VEGF and angiopoietin-2 together promote the invasive
proliferation of ECs, and inhibition of this process may be one mechanism of anti-TNFa drug activity
[75]. It is hoped that the complex paracrine pathways that promote angiogenesis may yield additional
therapeutic targets [76].
The role of adaptive immunity
T cells are one of the most abundant cell types in RA synovium, comprising 30–50% of synovial
tissue cells [77]. The majority are CD4þ, although CD8þ T cells are also present and may be of patho-
genetic importance [78]. At least amongst ACPA-positive individuals, the established genetic associa-
tions heavily implicate the CD4þ T ‘helper’ cell in the disease process. Naı¨ve CD4þ T cells can
differentiate into at least four broadly classiﬁed functional subgroups. In health, Th1 cells secrete
interferon g (IFNg) and defend against intracellular bacteria; IL-4-secreting Th2 cells combat extra-
cellular parasites; and the newly identiﬁed Th17 subset appears to defend against extracellular bacteria
such as Klebsiella pneumoniae; a further subset of regulatory T cells (T-regs) has a vital role in immune
tolerance and the modulation of established immune responses.
It now seems likely that Th17 cells represent a signiﬁcant player in human autoimmune inﬂam-
mation [79]. These cells survive in an environment characterized by IL-6, TGFb and IL-23 [80], where
they secrete IL-17. Through direct or indirect effects on various cell types, this highly pleiotropic
cytokine can induce inﬂammation, angiogenesis, osteoclastogenesis, and breakdown of bone and
cartilage. Several studies have demonstrated elevated IL-17 levels in blood and synovium of RA
patients, with correlations between synovial levels and joint damage [81,82]. T-regs appear to be
overrepresented in the synovium of RA patients, and evidence suggests that this may reﬂect their
functional impairment within the autoimmune microenvironment they are supposed to suppress [83].
Moreover, a compelling body of evidence now suggests that the T-cell population as a whole is
systemically abnormal in RA, having an excessive proliferative history; the result is a contracted T-cell
receptor repertoire and an immunosenescent phenotype [84]. Intriguingly, such premature ageing of
the immune system appears to predate the onset of clinical RA, and whether or not it represents
a signiﬁcant aetiological factor remains controversial.
The success of rituximab in the treatment of RA has conﬁrmed the importance of B cells in disease
pathogenesis [85]. Ectopic germinal-centre-like structures in the synovia of some patients create
a spatially organized microenvironment ideally suited to humoral immune responses. B cells can
process and present antigenic peptides to pre-primed CD4þ T cells, resulting in classical adaptive
humoral responses, and similar cognate interactions with B cells may prime naive T cells in some cases
[85]. In fact, co-ligation of the B-cell receptor (BCR) and TLR appears sufﬁcient to induce B-cell acti-
vation and antibody production independent of T-cell ‘help’, and this pathway is a proven mechanism
of rheumatoid factor (RF) autoantibody generation in experimental arthritis [86]. RF recognizes the Fc
portion of IgG molecules and is a characteristic, although not speciﬁc, hallmark of human RA, with
approximately 70% of patients being ‘seropositive’ [87]. Deposition of RF immune complexes occurs in
the rheumatoid synovium, where these complexes ﬁx complement, thereby reinforcing B-cell acti-
vation and perpetuating an Fc-receptor-mediated positive-feedback loop [85]. Rituximab therapy is
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tion, and neither is it absolutely conﬁned to the seropositive population [88]. As with ACPA, the precise
role of this autoantibody has therefore yet to be fully elucidated, but the RA synovium appears to
provide a context in which B-cell tolerance may be broken, autoantibody production enhanced, and an
aberrant immune response upheld.A ﬁnal common pathway
Cells of the monocyte–macrophage lineage and FLSs both represent important effectors of
cartilage and bone destruction in RA. A number of immune pathways converge on these cell types,
resulting in the deregulated production of pro-inﬂammatory cytokines such as TNFa and IL1b. TLR
ligation [89,90], contact with activated T cells [91], cytokines including IL-17 [92], Fcg-receptor
ligation by immune complexes, and the action of serine proteinases secreted by mast cells and
neutrophils probably all contribute [93]. Pro-inﬂammatory cytokines induce chondrocytes to secrete
cartilage-degrading enzymes, including matrix metalloproteinases (MMP) 1 and 13 and ADAMTS (a
disintegrin and metalloproteinase with thrombospondin motifs) 4 and 5. In fact, in the context of
such an inﬂammatory milieu, macrophages and FLSs adopt an ability to produce cartilage-degrading
enzymes directly. This is most evident at the interface between cartilage and inﬂamed synovium –
the so-called cartilage–pannus junction (CPJ), accounting for the striking invasiveness of the
inﬂammatory lesion in RA [94].
In the presence of macrophage colony-stimulating factor (M-CSF), and following engagement of
surface receptor activator of NFkB (RANK) by RANK ligand (RANKL), macrophages coalesce into
multinucleated syncytia or ‘giant cells’ uniquely equipped for bone resorption. Known as osteoclasts,
these cells are now widely acknowledged to be the primary mediators of periarticular bone erosion in
inﬂammatory arthritis [95]. Induced by pro-inﬂammatory cytokines, RANKL is expressed in abundance
by TH17 cells and the activated FLSs of the CPJ. Its expression is also enhanced by the presence of pro-
inﬂammatory cytokines and, it seems, TLR ligation [90].Summary
Evolving insights into the pathogenesis of the clinical entity we call ‘rheumatoid arthritis’
indicate that we are on the verge of being in a position to ‘split’ a hitherto ‘lumped’ collection of
conditions which share a degree of phenotypic overlap according to criteria that are of genuine
aetiopathogenetic signiﬁcance and clinical value (Fig. 2). There is every reason to hope that
continued progress in this area will yield new paradigms for the treatment of the condition, with
the choice of therapeutic agent being guided by the cellular and molecular peculiarities of the
individual patient – the true realization of ‘personalized medicine’. Tools for stratifying RA into
meaningful subsets in this way during the earliest phases of the disease are desperately needed, and
are the subject of intense investigation. Researching the pathogenesis of early RA is not for the
faint-hearted, but the potential gains in terms of outcomes for our patients, not to mention health
economics, should make the pursuit worthwhile.Practice points
 recently discovered genetic associations have provided new insights into RA pathogenesis
 many associations relate to the subset of patients who are ACPA autoantibody-positive,
suggesting distinct aetiologies for different disease subsets
 genetic and environmental inﬂuences lead to deregulation of several cellular and molecular
pathways, resulting in persistent joint inﬂammation and destruction.
Research agenda
 a better understanding of the various predisposing and triggering factors in early RA should
yield biomarkers of prognostic and therapeutic utility for this clinically heterogeneous
condition
 the precise relevance of ACPA autoantibody production amongst a subset of RA patients
remains an area of intense interest, despite considerable recent advances in the ﬁeld; insights
into the pathogenesis of ACPA-negative RA remain elusive.
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